The Street’s Key Stock Analysts Research Reports

The Street’s Key Stock Analysts Research Reports

The Street’s Key Stock Analysts Research Reports

$ALDX, $AMSC, $CARA, $CERN, $CNCE, $CTMX, $DRNA, $FEDU, $GLPG,  $INTC, $QCOM

Daily HeffX-LTN reviews dozens of  the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of the Street’s Key analysts outlook for main issues for Friday, as follows:

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) analysts  started as Buy and assigned a 21 fair value estimate at Janney. The firm likes its platform targeting inflammation with multiple upcoming catalysts, noting that Aldeyra is developing novel therapies to treat immune-mediated diseases and that its lead platform is designed to sequester reactive aldehyde species.

American Superconductor Corp. (NASDAQ:AMSC) was started with a Buy rating and assigned an 11 price target at Craig-Hallum. Shares have traded in a 52-wk range of 3.06 – 8.03, and 8.17 is the consensus target price.

Aquestive Therapeutics Inc. (NASDAQ:AQST) was started with an Outperform rating and assigned a 33 target price at Wedbush Securities. The firm considers Aquestive to be an opportunity to invest in proprietary PharmFilm technology that is being leveraged to develop a pipeline of 10 drugs and candidates and as an oral alternative in patients having difficulty swallowing pills or only having invasive options like injections.

Cara Therapeutics Inc. (NASDAQ:CARA) analysts started as Buy and assigned a 30 target price at Jefferies.

Cerner Corp. (NASDAQ:CERN) was started with an Equal Weight rating at Barclays.

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) was started as Neutral with a 17 fair value estimate at Janney.

CytomX Therapeutics Inc. (NASDAQ:CTMX) analysts started with a Buy rating and assigned a 32 price target at H.C. Wainwright. The 52-wk trading range is 16.26 – 35.00, and the consensus target price is at 39.33.

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) was started with a Buy rating and assigned a 27 price target at Citigroup.

Four Seasons Education Inc. (NYSE:FEDU) was downgraded to Sell from Neutral with a 4 price target at Citigroup.

Galapagos N.V. (NASDAQ:GLPG) analysts started with an Overweight rating at JPMorgan

Intel Corp. (NASDAQ: INTC) analyst raised INTC to Market Perform from Underperform with a 46 price target at Northland Securities. The consensus target price is at 56.06, and the 52-wk trading range is 36.16 – 57.60.

Qualcomm Inc. (NASDAQ:QCOM) analyst started with an Overweight rating and assigned a 95 price target at Barclays. Qualcomm has a 52-wk trading range of 48.56 – 72.75 and a consensus target price of 70.35.

Have a terrific weekend

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH